BridgeBio Pharma (BBIO) News Today $33.10 -0.24 (-0.72%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$33.08 -0.02 (-0.06%) As of 09:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BBIO Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period 185,000 Shares in BridgeBio Pharma, Inc. (NASDAQ:BBIO) Purchased by Jefferies Financial Group Inc.Jefferies Financial Group Inc. purchased a new position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 185,000 shares of the company's stock, valuedMay 28 at 7:04 AM | marketbeat.comTwo Sigma Investments LP Has $6.55 Million Stock Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Two Sigma Investments LP lowered its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 37.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 238,536 shares of the company's stock after selling 142,706 sharesMay 28 at 4:09 AM | marketbeat.comCetera Investment Advisers Takes $1.02 Million Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Cetera Investment Advisers acquired a new stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 37,163 shares of the companMay 26 at 3:29 AM | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Stock Position Raised by ProShare Advisors LLCProShare Advisors LLC increased its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 28.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 48,539 shares of the company's stock aftMay 24, 2025 | marketbeat.comFrazier Life Sciences Management L.P. Buys 40,000 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)Frazier Life Sciences Management L.P. boosted its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 1.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,800,457 shares of the company's stMay 23, 2025 | marketbeat.comWoodline Partners LP Raises Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Woodline Partners LP raised its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 132.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,211,521 shares of the company'sMay 22, 2025 | marketbeat.comZimmer Partners LP Acquires New Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Zimmer Partners LP purchased a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 180,400 shares of the company's stock, valued at approximatMay 22, 2025 | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Sells $871,779.48 in StockMay 21, 2025 | insidertrades.comBridgeBio’s Acoramidis: A Breakthrough in ATTR-CM TreatmentMay 21, 2025 | insidermonkey.comAcoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CMMay 20, 2025 | globenewswire.comTema Etfs LLC Invests $3.90 Million in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Tema Etfs LLC acquired a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 141,972 shares of the company's stock, valued at approximately $3,896,000. BridgeBio Pharma coMay 20, 2025 | marketbeat.comEarly and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM StudyMay 19, 2025 | globenewswire.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Bought by Sphera Funds Management LTD.Sphera Funds Management LTD. lifted its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 7.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 905,279 shares of the company's stock after acqMay 18, 2025 | marketbeat.comProsight Management LP Sells 91,810 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)Prosight Management LP cut its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 8.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 995,000 shares of the company's stock after sMay 17, 2025 | marketbeat.comNicholas Investment Partners LP Has $1.64 Million Stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Nicholas Investment Partners LP boosted its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 68.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 59,892 shares of the company's stock after acquiriMay 16, 2025 | marketbeat.comOctagon Capital Advisors LP Reduces Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Octagon Capital Advisors LP lessened its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 20.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 441,600 shares of the company's stock after sellingMay 15, 2025 | marketbeat.comInsider Selling: BridgeBio Pharma, Inc. (NASDAQ:BBIO) Major Shareholder Sells 6,000,000 Shares of StockMay 15, 2025 | insidertrades.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Bought by Janus Henderson Group PLCJanus Henderson Group PLC grew its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 1.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 4,907,533 shares of the company's stock after buying an additioMay 15, 2025 | marketbeat.comJefferies Financial Group Inc. Invests $5.08 Million in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Jefferies Financial Group Inc. acquired a new stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 185,000 shares of the company's stock, valued at approximately $5,076,000May 15, 2025 | marketbeat.com112,535 Shares in BridgeBio Pharma, Inc. (NASDAQ:BBIO) Acquired by Hudson Bay Capital Management LPHudson Bay Capital Management LP bought a new stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 112,535 shares of the company's stoMay 15, 2025 | marketbeat.comBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 14, 2025 | globenewswire.comWhy BridgeBio Pharma, Inc. (BBIO) Declined on TuesdayMay 14, 2025 | finance.yahoo.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) is Lion Point Capital LP's 6th Largest PositionLion Point Capital LP lessened its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 17.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 40,300 shares of the company's stock after sellMay 14, 2025 | marketbeat.comBridgeBio Pharma to Present Key Findings on Acoramidis at Heart Failure Association Congress 2025May 14, 2025 | nasdaq.comFirst Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention StudyMay 13, 2025 | globenewswire.comBrevan Howard Capital Management LP Reduces Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Brevan Howard Capital Management LP lowered its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 39.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,760 shares of the company's stockMay 13, 2025 | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Sold by Algert Global LLCAlgert Global LLC cut its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 82.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 23,600 shares of the company's stock after selling 112,8May 13, 2025 | marketbeat.comBridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESCMay 12, 2025 | globenewswire.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Acquired by Ensign Peak Advisors IncEnsign Peak Advisors Inc boosted its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 4.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,975,249 shares of the companyMay 12, 2025 | marketbeat.comNorthern Trust Corp Boosts Stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Northern Trust Corp boosted its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 3.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,323,258 shares of the company'May 12, 2025 | marketbeat.comRaymond James Financial Inc. Invests $456,000 in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Raymond James Financial Inc. bought a new stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 16,631 shares of the company's stock, valued at approximately $456May 12, 2025 | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) have earned a consensus rating of "Moderate Buy" from the twelve analysts that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold recommendation and eleven have assigned a buy recommendaMay 12, 2025 | marketbeat.comFarallon Capital Management LLC Purchases 2,448,000 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)Farallon Capital Management LLC grew its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 140.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,195,000 shares of the company's stock aMay 11, 2025 | marketbeat.comFrontier Capital Management Co. LLC Boosts Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Frontier Capital Management Co. LLC lifted its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 113.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,075,858May 11, 2025 | marketbeat.comCrestline Management LP Acquires 11,169 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)Crestline Management LP boosted its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 33.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 44,740 shares of the company's stoMay 11, 2025 | marketbeat.comCary Street Partners Financial LLC Invests $531,000 in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Cary Street Partners Financial LLC purchased a new stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 19,360 shares of the company's stock, valued at approximately $531,000. Several otMay 11, 2025 | marketbeat.comComerica Bank Buys 60,256 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)Comerica Bank grew its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 131.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 106,116 shares of the company's stock after purchasing an aMay 10, 2025 | marketbeat.comAQR Capital Management LLC Has $6.14 Million Stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO)AQR Capital Management LLC boosted its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 14.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 223,573 shares of the companyMay 10, 2025 | marketbeat.comDeep Track Capital LP Invests $22.48 Million in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Deep Track Capital LP bought a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 819,162 shares of the company's stock, valued at aMay 9, 2025 | marketbeat.comCutter Capital Management LP Acquires 163,956 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)Cutter Capital Management LP increased its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 41.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 560,344 shares of the company's stock after acquiring an additional 163,956 shares duringMay 8, 2025 | marketbeat.comBridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025May 7, 2025 | globenewswire.comMaricel Apuli Sells 1,026 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) StockMay 7, 2025 | insidertrades.comAlyeska Investment Group L.P. Makes New $25.81 Million Investment in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Alyeska Investment Group L.P. purchased a new stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 940,415 shares of the company's stock, valued at approximaMay 7, 2025 | marketbeat.comCantor Fitzgerald Has Positive View of BBIO FY2025 EarningsBridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Stock analysts at Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for BridgeBio Pharma in a report issued on Wednesday, April 30th. Cantor Fitzgerald analyst J. Schimmer now expects that the company will earn ($3.93) perMay 4, 2025 | marketbeat.comThe Manufacturers Life Insurance Company Boosts Stock Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)The Manufacturers Life Insurance Company increased its position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 23.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,885,794 shares of the company's stock afMay 3, 2025 | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Bought by Price T Rowe Associates Inc. MDPrice T Rowe Associates Inc. MD grew its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 22.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 991,238 shares of the compMay 3, 2025 | marketbeat.comBridgeBio Pharma (NASDAQ:BBIO) Sets New 52-Week High on Earnings BeatBridgeBio Pharma (NASDAQ:BBIO) Reaches New 12-Month High After Strong EarningsMay 2, 2025 | marketbeat.comUBS Group Issues Positive Forecast for BridgeBio Pharma (NASDAQ:BBIO) Stock PriceUBS Group increased their target price on shares of BridgeBio Pharma from $65.00 to $72.00 and gave the stock a "buy" rating in a research note on Wednesday.May 2, 2025 | marketbeat.comBridgeBio Pharma (NASDAQ:BBIO) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPSBridgeBio Pharma (NASDAQ:BBIO - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.88) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.02.May 1, 2025 | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Holdings Reduced by Emerald Mutual Fund Advisers TrustEmerald Mutual Fund Advisers Trust cut its position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 3.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 724,872 shares of the company's stock after selling 26,483 shares durinMay 1, 2025 | marketbeat.com Get BridgeBio Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address BBIO Media Mentions By Week BBIO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BBIO News Sentiment▼1.031.03▲Average Medical News Sentiment BBIO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BBIO Articles This Week▼89▲BBIO Articles Average Week Get BridgeBio Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Beigene News BioNTech News Teva Pharmaceutical Industries News Summit Therapeutics News Intra-Cellular Therapies News Genmab A/S News Dr. Reddy's Laboratories News Moderna News Ascendis Pharma A/S News Viatris News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BBIO) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredDollar Collapse Warning: Protect Your Wealth NOWGlobal central banks are stockpiling gold. Billionaires are hedging with precious metals. And thousands of Ame...Lear Capital | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BridgeBio Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BridgeBio Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
